GLP-1 drugs have contributed significantly to health care cost trend in recent years, while also providing enhanced clinical outcomes to patients. This session will address key considerations for actuaries at health care payors, PBMs, and employers such as:
Can this clinical outcomes data, such as member biometric data on A1C values and BMI, be used to predict a member's health care costs?
How and when will these enhanced clinical outcomes manifest in Lower health care costs? How would actuaries measure this long term health care cost impact?
How will an actuary measure which GLP1 plan design and management programs/products have been shown to drive the best outcomes for patients, and be the most cost effective?
Through real-world data and case studies, this session will explore approaches to answering these important questions.